Candel Therapeutics Details CFO Charles Schoch's Employment Terms

Candel Therapeutics, Inc. entered into an employment agreement with its Chief Financial Officer, Charles Schoch, on June 12, 2026. The agreement outlines the terms of his continued at-will employment, maintaining his annual base salary of $468,600 and eligibility for an annual bonus targeted at 40% of his base salary. The agreement also details severance provisions, including nine months of base salary plus target annual bonus, and up to nine months of COBRA health coverage continuation, upon termination without cause or for good reason. Additionally, all time-based equity awards will fully accelerate if his employment is terminated under specific conditions related to a change in control.